https://www.selleckchem.com/pr....oducts/epz020411.htm
However, there is no conclusive information for most of the therapeutic regimens due to the lack of high-level evidence. Inflammatory markers or neutrophil-lymphocyte-ratio may be applied as indicators for clinical prognosis or therapeutic regimens adjustment. Thus, more research is still needed to address the prevalence, treatment, and clinical monitoring of RADs patients in COVID-19 pandemic.Background Genetic association studies have identified single nucleotide polymorphisms (SNPs) associated with lasting lung diseases such as Chr
Like
Comment
Share
